Biogen/Elan Submit Applications For Tysabri Label Change Ahead of Schedule

In a bid to solidify Tysabri's place in an increasingly competitive market, Biogen/Elan push forward with changes to the multiple sclerosis medicine's label that help define the risk of a rare brain infection.